Gender and Migration: An Integrative Approach

This paper is a synopsis of Oishi’s forthcoming book Women in Motion: Globalization, State Policies, and Labor Migration in Asia (Stanford University Press), which analyzes the mechanisms involved in international female migration in Asia. Acknowledging the shortcomings of previous studies that focus too much on migrantreceiving countries and/or a single country case, this work examines female migration from a comparative and integrative perspective. The analysis proceeds at multiple levels of analysis: (1) the state (macro); (2) individuals (micro); and (3) society (meso) in both migrant-sending and receiving countries. How have foreign direct investment and state policies affected women’s labor force participation? How has society legitimized or illegitimized women’s labor migration within and across national borders? How do individual women make their decisions to emigrate? Based on fieldwork in 10 countries, the study demonstrates the complex causation of international female migration in Asia

Effect of exenatide on oxaliplatin-induced neurite degeneration in cultured PC12 cells.

<p>Cultured PC12 cells were incubated with oxaliplatin (3 μM) for 24 h in the presence or absence of exenatide (3, 10, or 30 nM). (A) Photographs were originally magnified 800 ×. Scale bar = 100 μm. (B) Neurite length was measured using image analysis software (MetaXpress). Results are expressed as the mean ± standard error mean (<i>n</i> = 3). **<i>P</i> < 0.01 compared with control, ††<i>P</i> < 0.01 compared with oxaliplatin alone.</p

Effects of extended-release exenatide on recovery from mechanical allodynia and axonal degeneration induced by oxaliplatin.

<p>Oxaliplatin (4 mg/kg) was administered i.v. twice per week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22, and 23). Extended-release exenatide (100 μg/kg) was administered s.c. once per week for 9 weeks (days 1, 8, 15, 22, 29, 36, 43, 50, and 57). Oxaliplatin treatment ceased on day 23, however exenatide treatment was continued for an additional 5 weeks. (A) The von Frey test was performed before the first drug administration (on day 0) and on days 35, 42, 49, 56, and 63. Values are expressed as the mean ± standard error mean of five to six animals. (B) On days 42 and 63, the sciatic nerve was harvested, and samples were stained with toluidine blue. Images were captured at 800× magnification. Scale bar = 60 μm. (C) The area of axon (number of axon: from 3000 to 6000/field) was measured using image analysis software (Image J 1.36). Values are expressed as the mean ± standard error mean of four animals. *<i>P</i> < 0.05, **<i>P</i> < 0.01 compared with vehicle, ††<i>P</i> < 0.01 compared with oxaliplatin alone.</p